Bisabolol

The isomer matters

Bisabolol is a sesquiterpene alcohol, but the research in this set usually specifies alpha-bisabolol. A report that says only “bisabolol” may leave that detail unresolved. Keep the exact isomer with the laboratory result when comparing a certificate of analysis with a paper. The MCPH terpene reference keeps the naming question separate from product claims.

Two preclinical lines of work

One 2004 study exposed human and rat glioma cells to isolated alpha-bisabolol and measured viability and apoptosis markers. A different study examined alpha-bisabolol at Cav3.2 T-type calcium channels and then used mouse pain models. These are cell, channel and animal experiments using an isolated compound. They describe model responses, not treatment in people.

A certificate of analysis answers a narrower question

If bisabolol appears on a product report, the entry records a constituent detected or measured by that method. It does not show whether the result is alpha-bisabolol, whether the concentration resembles either experiment or how the complete formulation behaves. NHS medical-cannabis information and the Home Office factsheet supply the product context; neither source turns bisabolol into a clinical marker.

The cited work does not establish clinical pain relief, cancer treatment, safety or suitability for a labelled cannabis product. Those boundaries belong beside the model findings, not in a separate promise about what the name might do.

Related conditions

• Neuropathic pain
• Arthritis and joint pain

Sources

• Alpha-bisabolol and glioma cells (primary cell/laboratory study, PMID 14975741, DOI 10.1016/j.bbrc.2004.01.088).
• Camphene and alpha-bisabolol at Cav3.2 channels (primary cell/laboratory and mouse study, PMID 34775970, DOI 10.1186/s13041-021-00876-6).